Resources from the same session
LBA11 - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
Presenter: Aditya Bardia
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Presenter: Aaron Lisberg
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
LBA13 - Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
Presenter: Oliver Sartor
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA13
Presenter: Christopher Sweeney
Session: Presidential 3
Resources:
Slides
Webcast
LBA14 - Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial
Presenter: Byoung Chul Cho
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
LBA15 - Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
Presenter: Antonio Passaro
Session: Presidential 3
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA14 and LBA15
Presenter: Zofia Piotrowska
Session: Presidential 3
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Presidential 3
Resources:
Webcast